...WASHINGTON LONDON and HONG KONG March 30 2011 /- Super... We are delighted to announce this agreement with KSB Diagnostics a l... About Neopterin ...Neopterin is an analyte of growing interest throughout the world for t...

WASHINGTON, LONDON and HONG KONG, March 30, 2011 /PRNewswire/ -- SuperNova Diagnostics®, Inc., a privately-held global diagnostics company for human and non-human health applications, announced today that it has signed an agreement with Shenzhen Kang Sheng Bao Bio-Technology Co., Ltd. ("KSB"), a biotechnology diagnostics company specializing in research, manufacture and distribution of in-vitro diagnostic kits and research reagents in China and affiliated markets for the research, development, manufacture and commercialisation of diagnostic products and services for the measurement of Neopterin, its metabolites and derivatives utilising the SuperNova technology platform of AmpCrystal®. Financial terms of the agreement were not disclosed.

"We are delighted to announce this agreement with KSB Diagnostics, a leader in China and Asia for diagnostics," said Neil Campbell, president & CEO of SuperNova Diagnostics. "This collaborative agreement allows SuperNova and KSB to expand R&D, manufacturing and commercialisation of a proprietary set of biomarkers for acute and chronic inflammatory conditions into one of the world's largest markets initially and then potentially rest of the world."

About Neopterin

Neopterin is an analyte of growing interest throughout the world for the detection, monitoring and prognosis of acute and chronic inflammatory responses and is thought to be implicated in over 80 different inflammation-mediated diseases such as cardiovascular, CNS, infectious disease, respiratory and cancer.

About AmpCrystal® Technology

AmpCrystal®, SuperNova Diagnostics' lead technology with multiple product formats, allows for minimally trained individuals (advanced CLIA-waived) to test for a wide range of protein analytes and can detect directly un-amplified DNA in humans, animals or environmental samples. AmpCrystal® is hyper-dense, energy-mediated proprietary nanocrystals that can be utilised in a wide variety of diagnostic applications and configurations. The technology platform lends itself to both forward-integration into new product formats as well as backward compatible into existing open and closed diagnostic systems.

Time-to-result has been shown in prototypes to be reduced to minutes on the spot versus the hours or days required when sending samples to a central laboratory or processing in regional satellite laboratories. With three integrated capabilities (sample collector/processor, analytical disposable, and the readout device), the technology is simpler, more robust, faster and significantly less expensive than existing POC systems.

About Shenzhen Kang Sheng Bao Bio-Technology Co. Ltd "KSB"

KSB provides innovative diagnostic kits and technologies to serve the large developing market in China and is a leader in vitro diagnostic reagents, OEM manufacture and contractual R&D and through partnerships possesses products with international brand (such as drugs, medical devices, bio-products, diagnostic kits, scientific research instruments, etc.), and has business relations with more than 30 countries and regions.

About SuperNova Diagnostics®, Inc.

SuperNova® is a development-stage diagnostics company with a proprietary platform for conducting diagnostics at the site of interest with point-of-care in human health and point-of-use for non-human health applications. A powerful proprietary nanochemistry, AmpCrystal®, can deliver novel, next generation performance for pathogens, proteins, and directly measure DNA without PCR with ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements. SuperNova can be utilized in a wide range of diagnostic formats (lateral flow, self-contained cartridges, microtitre, microarrays, closed systems, research products and OEM). SuperNova® - Putting the Laboratory in the Palm of Your Hand®.

(Date:12/8/2016)... , Dec. 8, 2016 Biotheranostics today announced ... role of the Breast Cancer Index (BCI) in ... cancer are most at-risk for disease recurrence and ... results from three studies advancing the understanding of ... to tumor biology and inform decisions related to ...

(Date:12/8/2016)... USA, and CARDIFF, UK (PRWEB) , ... December ... ... with very high precision light to control cells — optogenetics — is key ... the current state of the art, spatially patterned light projected via free-space optics ...

(Date:12/7/2016)... According to a new market research report "Emotion Detection ... Voice Recognition), Service, Application Area, End User, And Region - Global Forecast to ... 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a Compound ... ... MarketsandMarkets Logo ...

(Date:12/6/2016)... WARSAW, Ind. , Dec. 6, 2016 Zimmer Biomet ... that it has priced an offering of €500.0 million principal ... €500.0 million principal amount of its 2.425% senior unsecured notes ... is expected to occur on December 13, 2016, subject to the ... on an annual basis. ...